Activation of the c-myc proto-oncogene, in the form of DNA rearrangements that lead to constitutive expression, has been implicated in the genesis of a wide range of tumors. Therefore, it is of great interest to determine the influence of c-myc oncogene activation on cellular growth control, especially in primary cells. To facilitate the efficient transfer of an activated c-myc oncogene, we developed a mouse retrovirus that contains the. c-myc protein-coding sequences and which can be transmitted in the presence of a Moloney murine leukemia virus helper or established as a helper-free stock with a retrovirus-packaging cell line. The virus can transform established lines of mouse fibroblasts to anchorage-independent growth; the transformed cells are tumorigenic in nude mice. However, the virus was not capable of inducing foci of transformed cells on confluent monolayers. In addition to studies on established cell lines, the effect of the c-myc retrovirus on primary cells was examined. Infection of bone marrow cells gave rise to partially transformed mononuclear phagocytes which were entirely dependent upon an exogenous supply of the monocyte-specific colony-stimulating factor CSF-1 for proliferation. Infection in vivo induced monocyte-macrophage tumors with a latency period of 8 to 10 weeks.
Cellular proto-oncogenes were first discovered when it was found that the transforming genes within the acutely oncogenic retroviruses were derived from cellular sequences that were highly conserved in evolution and expressed in normal tissues (for a review, see reference 3). Subsequent studies have found that the activation of cellular protooncogenes by mutation (26, 30, 31) , chromosomal translocation (10, 27, 32) , and gene amplification (1, 7, 9 ) is linked to the induction of many types of cancer. More specifically, activation of one particular proto-oncogene, c-myc, has been found frequently in lymphoid neoplasia (8, 10, 27, 29, 32) and lung carcinomas (20) . Yet, despite the association between c-myc activation and tumors, it is not known what role the c-myc gene, or any particular oncogene, has in malignant transformation. Therefore, it is of great interest to study the influence of c-myc oncogene activation on the growth properties of the normal cells from which the cancers originate.
One approach toward understanding the role of oncogene activation in cell transformation is to transfect the activated oncogenes as DNA into recipient cells for studies of oncogene-induced changes in cellular phenotype. This is limited by the difficulty in introducing foreign DNA into many cell types, especially hemopoietic cells. One efficient approach for the introduction of an activated oncogene into recipient cells is by means of a retrovirus. Indeed, the naturally arising, oncogene-containing retroviruses have been used for many years to study cell transformation both in vitro and in vivo (for a review, see reference 36). In the case of the myc oncogene, three independently isolated avian retroviruses have been studied which are capable of inducing a wide range of neoplastic diseases (for a review, see reference 11 ). Yet, no myc retrovirus has ever been isolated from mice or other rodents. The availability of such a virus would be of exceptional value since it should allow the influence of c-myc activation to be studied in an organism in which a great deal is already known about the hemopoietic system and the ontogeny of cells of myeloid and lymphoid * Corresponding author.
lineage. Furthermore, mouse B and T cell tumors have frequently been associated with activation of the cellular gene (8, 27, 29) .
To facilitate further studies on the response of normal cells to oncogene activation, we describe the construction and characterization of a mouse retrovirus that contains the protein-coding exons from the cellular myc oncogene (MRV). This virus is capable of transforming NIH 3T3 cells to an anchorage-independent, tumorigenic phenotype and of partially transforming bone marrow-derived macrophages, properties similar to those recently described for a murine retrovirus containing the OK10-derived avian v-myc gene (34) . MRV (27) and has no known mutations.
Constructs and RNA and DNA analysis. The pEVXmycXH construct was prepared by inserting a segment of the mouse c-myc gene into the pEVX vector (15) . The mnycXH2 cell line has been described previously (15) . RNA and DNA from cell lines and tumors were extracted and analyzed as described previously (16) .
Cloning efficiencies in soft agar. Characterization of anchorage-independent growth properties of myc-infected cells was performed by soft agar cloning of 5 x 10' viable cells in 0.26% agar over a 0.65% lower layer in 60-mm culture dishes. Plates were scored for colonies at 14 days after seeding.
Tumorigenicity assays. Tumorigenicity assays were performed essentially as described by Blair et al. (4) 24 h to enhance viral adsorption and then were plated into soft agar as described above. For in vivo infections, MRV (in 1.0 ml of filtered supernatant) was injected intraperitoneally into 8-to 10-week-old BALB/c or DBA/2 mice. Where indicated, mice were pretreated with a 0.5-ml intraperitoneal injection of pristane (Aldrich Chemical Co., Inc.) 3 to 4 weeks before virus infection. For in vitro infections, 2 x 106 spleen or bone marrow cells from 4-to 6-week-old BALB/c mice were incubated in 2 to 3 ml of filtered supernatant from virus-producing cells (helper dependent or helper free) for 24 h in the presence of 8 ,ug of Polybrene (Sigma) per ml. Virus infection was repeated 2 to 3 times, after which the cells were pelleted, suspended in 1.0 ml of PBS, and injected intraperitoneally.
Tumors were diagnosed by the visible accumulation of ascites fluid after 8 to 12 weeks. Dissection revealed a high concentration of tumor cells in the ascites fluid, thickening of the peritoneal wall, and some small tumor masses. There was no enlargement of the spleen, thymus, or lymph nodes.
Tumor cell characterization. Tumor DNA was extracted from the ascites tumor cells and analyzed as described previously (16) . Cytological markers were analyzed for tumor cells cultured in RMPI 1640 supplemented with 10% fetal calf serum by the following protocols. Nonspecific esterase was determined as described by Yam et (Fig. 1) . Previous results indicated that the clone, NIH/mycXH2, contained a single copy of the transfected pEVX-mycXH construct and expressed two predominant RNA species which hybridize to both Mo-MuLV-LTR and c-myc sequences (15) . In addition, the pEVX-mycXH construct was transfected into the cell line tP2, which contains a nonpackageable helper virus genome (24) , to yield the cell line P2rnyc8.
The pEVX-XH construct was transcribed into two predominant RNAs of 3.0 and 2.5 kilobases (kb) in NIH/mycXH2 cells (15) . To analyze the sequences within these RNA species, Northern blots of poly(A)-containing RNA were hybridized to the nick-translated probes indicated in Fig. 1 . The LTR probe (probe a) hybridized to both of the predominant 3.0-and 2.5-kb RNA species (Fig. 2 , lane a), as well as to a 4.0-kb precursor RNA evident upon longer exposure. These RNAs were also detected with the second and third c-myyc exons (Fig. 2 , lanes c and e, respectively).
To determine which of these RNA species contained the packaging site required for viral RNA rescue, blots were probed with a 0.30-kb RsaI-BglII fragment from the MoMuLV intron region which is 3' to the Mo-MuLV splice donor site (probe b, Fig. 1 ). This intronic probe detected only the larger 4.0-kb full-length precursor RNA and the 3.0-kb transcript ( Characterization of the c-myc proviral structure. To determine the structure of an integrated c-myc provirus, transformed fibroblasts isolated from soft agar colonies (MRV3 and MRV5 cell lines) were grown to large scale. These MRV cells were more refractile than either the parental NIH 3T3 cells or the Mo-MuLV-infected NIH/myc XH2 cell line. There were also large numbers of floating cells, and the entire monolayer detached from the plate when the cultures reached confluence without forming colonies that overgrow the monolayer. This observation may account for the lack of foci of transformed cells when monolayers of infected cells were analyzed at confluence (data not shown).
DNA was extracted from the MRV3 and MRV5 cell lines and analyzed by Southern blotting with a c-myc second exon probe. This probe detected a single exogenous HindIII fragment in NIH/mycXH2 cells which was derived from the transfected pEVX-mycXH construct (Fig. 4) . Both MRV3 and MRV5 DNAs have single unique exogenous bands, indicating that new c-myc genes have been introduced into these cells as a consequence of MRV transformation. The intensity of each novel band is less than that of the endogenous c-myc fragments, consistent with the presence of a single c-mnyc provirus per cell. The exogenous c-mychomologous sequences in the MRV DNAs were shown to be derived from similar proviruses by digestion with XbaI, which cleaves within the LTRs and within the c-myc intron (Fig. 1) . Hybridization of XbaI-digested NIH/mycXH2 DNA to a c-myc probe yielded a 3.0-kb band, which is consistent with the initial construct. Both of the MRV DNAs, however, showed a common 1.9-kb XbaI fragment, consistent with (Fig. 4) . Thus, the structure of the integrated c-myc provirus is consistent with the diagram in Fig. 1 .
c-myc expression in MRV cell lines. RNA transcripts arising from the retrovirally introduced c-myc gene were analyzed in Northern blots of poly(A)-containing RNA isolated from MRV cell lines and controls. In both the MRV3 and MRV5 cell lines, c-myc RNAs of 3.0 and 2.5 kb were found (Fig. 5) . These RNAs comigrate with the c-myc RNAs found in the Mo-MuLV-infected NIH/mvcXH2 cell line. The level of proviral myc RNA was somewhat higher than that found in the NIH/mycXH2 cell line, in which the exogenous c-myc gene was introduced by transfection.
Tumorigenicity of cell lines containing an integrated c-myc provirus. To further assess the phenotype of cell lines containing c-mvc proviruses, 2 x 106 cells from the virusinduced soft agar clones were injected subcutaneously into nude mice, and the animals were examined for tumor development. Both MRV3 and MRV5 cell lines were strikingly tumorigenic, with progressive tumors evident 2 to 3 days postinjection (Table 1) . Moreover, the onset of tumor development was more rapid with these cell lines than with the NIH/mycXH2 cell line. Analysis of tumor DNA indicated that the tumors arose from the MRV cell lines because they contained the same proviral junction fragments (data not has contributed to their increased efficiency of anchorageindependent growth.
Transformation of bone marrow cells. The majority of the tumors in which activated c-mvn' genes have been implicated are of hemopoietic lineage. Therfore, we assayed MRV for the ability to induce partial or complete transformation of bone marrow cells from 4-week-old mice. The infected cells were cultured in medium containing 10% fetal calf serum alone or 10% fetal calf serum supplemented with the growth factor CSF-1 (from L cell-conditioned medium). CSF-1 is a principal mitogen for the monocytic lineage in the mouse (6, 12, 33); this lineage is the primary target cell type for avian retroviruses (11) .
Bone marrow cells were analyzed for both colony formation in soft agar and extended proliferation in culture. In the soft agar colony assay, MRV induced numerous tightly packed, anchorage-independent colonies, but only in the presence of CSF-1-supplemented medium (data not shown). These results are similar to those reported for a mouse retrovirus expressing the avian v-my(n gene (34) . There were no soft agar colonies in the absence of added CSF-1 or with MRV infection alone. A small number of colonies with a more diffuse shape were found with growth factorsupplemented medium. In culture, MRV induced extensive long-term proliferation of mononuclear phagocytic cells, but only in the presence of CSF-1-containing medium. With CSF-1-supplemented medium alone, there was an initial proliferation of macrophagelike cells, but these cells senesced rapidly. There was no cell growth, with MRV alone, beyond that observed with uninfected primary bone marrow cultures. The bone marrow cells partially transformed in vitro could be propagated in the presence of CSF-1 " The influence of pristane on tumor incidence was analyzed by injection of 0.5 ml intraperitoneally 28 days before virus infection.
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and were somewhat rounded, although they were quite adherent and phagocytic (data not shown). The MRVtransformed bone marrow cells can be assigned to the mononuclear phagocyte lineage because only cells of this stage express receptors for the growth factor CSF-1 (6, 12) .
The growth of the MRV-transformed macrophages was dependent upon a continuous supply of exogenous CSF-1. When cells partially transformed by c-myc in the presence of exogenous CSF-1 were transferred to unsupplemented medium, they stopped proliferating and began to die immediately, whereas cells cultured with CSF-1 grew vigorously (Table 2) . Thus, MRV can partially transform macrophagelike cells in culture, but the cells are absolutely dependent upon an exogenously supplied hemopoietic growth factor.
Induction of monocytic tumors. We also investigated the in vivo oncogenic potential of MRV. Filtered supernatants from MRV-infected cells and from control cells producing only the Mo-MuLV helper virus were injected intraperitoneally into 8-to 10-week-old BALB/c mice. Approximately 101 to 104 CFU of MRV were injected per animal. Some animals were also injected with the mineral oil pristane before virus infection. Pristane-treated mice preferentially showed rapid signs of neoplastic disease, usually from 8 to 10 weeks after infection (Table 3 ). Abdominal swelling was followed by rapid loss of vitality (anemia) and death after about 2 weeks. Ascites fluid, thickening of the peritoneal wall, and tumor masses within the abdominal cavity characterized these neoplasias. The ascites fluid was found to contain a high density of transformed cells with monocytic morphology (data not shown) and characteristics (see below). No spleen, thymus, or lymph node enlargement was observed in MRV-infected mice, which clearly distinguished them from the control mice infected only with Mo-MuLV.
The latter displayed the gross enlargement of these organs " Mononuclear phagocytic cells derived from transformattion of bone marrow cells in culture were expanded in the presence of CSF-1-supplemented medium (RPMI 1640 with 109/ fetal calf serum and 10% (vol/vol) L cell-conditioned medium). Cells (105) were seeded into plates in the same medium. After 24 h, the mediuim on the plate withotit CSF-1 was replaced with fresh medium without CSF-1. The cells were counted at the indicated time.
CSF-1 wats removed on day 1.
There were at small nuimber of dead or dying cells still attached to the plate. J. VIROL. [19] ). The bands at 2.5 and 3.0 kb in the helper-free tumors derived from the introduced c-mvc provirus (Fig. 4) . The band at 8 kb apparently derived from low levels of endogenous retroviral genome transcription; similar bands were found in WEHI-3, P388D1, and mycXH2T fibroblasts which were not infected with retroviruses. characteristic of Mo-MuLV-induced thymic lymphomas, which usually appears at much later times (3 to 6 months).
Cells derived from the ascites fluid of MRV-infected mice could be passaged intraperitoneally through non-pristanetreated mice, causing death within 2 weeks. Induction of myeloid tumors was not specific to BALB/c mice because identical results were obtained with MRV infection of pristane-primed DBA/2 mice (Table 3) .
Helper-free virus infection. The helper-free virus stock (k42mycB) was also analyzed for oncogenic potential. Primary cells were isolated from bone marrow or spleens of BALB/c mice and incubated with filtered supernatants containing MRV with or without helper virus. After 1 to 3 days of in vitro infection, the cells were collected by centrifugation and injected intraperitoneally into pristane-primed BALB/c mice. These mice developed tumors which were identical to those observed with the helper-dependent virus in vivo, with similar kinetics, i.e., 8 weeks postinjection (Table 3) (14) . Lysozyme activity, nonspecific esterase staining, and phagocytosis are specific markers for mononuclear phagocytes (23, 25, 37) . Analysis of each of these markers placed the MRV-induced tumor cells in the monocytic or macrophage differentiation pathway (Table 4) . For comparison, control cell lines were included which represent known differentiative stages of murine hemopoiesis. The myelomonocytic leukemia cell line WEHI-3 represents a stage before commitment to either granulocytic or mononuclear phagocytic pathways (22) , and P388D1 is a murine macrophage cell line (18) . One MRV-induced tumor cell line, 9.1.1, gave consistently lower values for markers that are specific for more mature mononuclear phagocytes ( (27) . From the Northern blot in Fig. 4 , it is estimated that the level of the 2.5-kb MRV RNA is fourfold higher than the 2.4-kb endogenous c-myc transcript in NIH 3T3 cells. The transforming activity of MRV in this study contrasts somewhat with a previously described OK10-derived v-myc virus (34) in that we were unable to detect foci of transformed cells in fibroblast monolayers.
Bone marrow-derived mononuclear phagocytes (macrophagelike cells) can be partially transformed in vitro by MRV. The outgrowth of c-myc-transformed bone marrow cells was absolutely dependent upon the addition of the growth factor CSF-1. Furthermore, the extended proliferation of these cells in culture required a continuous supply of the same factor. These results suggest that, unlike the findings that myc expression can partially eliminate the need for platelet-derived growth factor in fibroblasts (2) or IL-2 and IL-3 in hemopoietic cells (24) , constitutive c-myc expression cannot eliminate the need for CSF-1 in monocytes. It will be interesting to study the relationship between c-myc expression and other oncogenes and growth factors in cells of the myeloid lineage. A recent study has demonstrated that bone marrow-derived macrophages can be immortalized in vitro by a raf-myc recombinant retrovirus in the absence of exogenous growth factors (5) .
Numerous studies, largely from Graf and Beug (for a review, see reference 11), have investigated the transforming activity of the avian myc-containing retroviruses both in vivo and in vitro. The principal disease induced by the prototype myc virus, MC29, is myelocytomatosis, with which the neoplasm described in this study shares many features. One of the most striking aspects is the uniformity of the specific maturational stage and lineage of the transformed cells, in particular the mononuclear phagocytic target cells. In each case, the transformed cells resemble fully differentiated macrophages for the majority of the myeloid cell stagespecific markers. However, chicken myelocytomatosis is a somewhat more rapid disease, killing the animals in 4 to 5 weeks (11) as compared with visible ascites formation, which usually occurs in 8 to 10 weeks in BALB/c mice or 12 to 20 weeks in DBA/2 mice followed by death 2 to 3 weeks later. It is possible that transformation by MC29 may result from a higher level of expression in virus-infected cells or mutations within the v-myc protein or both, as compared with the cellular myc protein (13, 35) . In contrast, the murine virus used in this study expressed c-myc at a level which was at most fourfold higher than that of the endogenous gene in proliferating cells lacking activated c-myc genes (Fig. 5) 
